Drug Profile
Research programme: macrocyclic compounds - Cyclenium Pharma
Alternative Names: Cancer therapeutics - Cyclenium/Southern Research Institute; Cancer therapeutics - Cyclenium/University of Montreal; Gastrointestinal and metabolic disorders therapeutics - Cyclenium; Immunological disorder therapeutics - Cyclenium/University of Montreal; Infectious diseases therapeutics - Cyclenium/Fundación MEDINA; Infectious diseases therapeutics - Cyclenium/Southern Research Institute; Inflammation and pain therapeutics - Cyclenium; Neurological disorder therapeutics - Cyclenium/Southern Research InstituteLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Cyclenium Pharma
- Developer Cyclenium Pharma; Fundacion MEDINA; SickKids; Southern Research Institute; University of Montreal
- Class Macrocyclic compounds; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Gastrointestinal disorders; Metabolic disorders
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders; Immunological disorders; Infections; Neurological disorders
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for research development in Cancer in USA
- 28 Jan 2024 No recent reports of development identified for research development in Cardiovascular-disorders in USA
- 28 Jan 2024 No recent reports of development identified for research development in Immunological-disorders in USA